Bayzed Health Group Inc has issued a notice convening its Annual General Meeting (AGM) for 10:00 a.m. on 16 June 2026 at Room 2401, Mingfeng Building, Fengtai District, Beijing. Key matters for shareholder approval are as follows:

1. Financial Statements • Receive the audited consolidated results and the directors’ and auditors’ reports for the year ended 31 December 2025.

2. Board Composition • Re-election of four executive directors: Xu Xu, Dr Chen Haoyang, Lu Jizhong and Feng Yu. • Appointment of Lyu Chao as a new executive director. • Re-election of three independent non-executive directors: Chan Hok Leung, Liu Shuang and Dr Guo Wei. • Board authorised to set individual director remuneration.

3. Auditor • Proposed re-appointment of KPMG, with remuneration to be fixed by the board.

4. Share Repurchase Mandate • Directors to receive a 10 % general mandate to repurchase and cancel, or hold as treasury, shares in compliance with Hong Kong Listing Rules.

5. Share Issuance Mandate • Directors to be granted a 20 % general mandate to allot and issue new shares, inclusive of potential sale or transfer of treasury shares. • Rights issues, share-option exercises and scrip dividends are excluded from the 20 % cap.

6. Extended Issuance Capacity • Conditional extension of the 20 % issuance mandate by the number of shares repurchased under the 10 % buy-back authority, effectively lifting total potential issuance to 30 % of the issued share capital.

7. Articles of Association • Adoption of a third amended and restated Articles of Association, incorporating all proposed amendments outlined in the company’s circular dated 22 May 2026.

Logistics and Voting • All resolutions will be decided by poll. • The register of members will close from 11 June to 16 June 2026 (both dates inclusive); shareholders must lodge share transfers by 4:30 p.m. on 10 June 2026 to qualify for attendance and voting rights. • Proxy forms must be submitted to Tricor Investor Services Limited by 10:00 a.m. on 14 June 2026.

Shareholders are advised to review the accompanying circular and 2025 Annual Report for detailed information on each agenda item.